Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial. (PubMed, Nat Commun) - Oct 8, 2026 - P2 | "Circulating tumor DNA cleared by week 6 in 20 of 30 evaluable patients (66%). These findings support randomized evaluation of interleukin-1β blockade in this setting."
Journal • P1/2 data • Cardiovascular • Fatigue • Febrile Neutropenia • Hematological Disorders • Hypertension • Infectious Disease • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Oncology • Pneumonia • Respiratory Diseases • Solid Tumor • CD8 • CTLA4 • IL1B
|
|
Abraham J Wu; Afsheen Iqbal; Andreas Rimner; Annemarie F Shepherd; Bobby Daly; Boris Mueller; Charles B Simone; Daniel R Gomez; Daphna Y Gelblum; Fernando C Santini; Helena Yu; Isabel Preeshagul; Jacob Y Shin; Jamie E Chaft; Jasme Lee; Juliana Eng; Karmelina Charalambous; Kenneth Ng; Mark G Kris; Michael Berger; Michael Offin; Michelle S Ginsberg; Nancy Y Lee; Narek Shaverdian; Nicolas Toumbacaris; Paul Paik; Phillip Wong; Richard Gewanter; Ronak Shah; Ronglai Shen; Zhigang Zhang
|